Centre for Human Genetics, Building for Genomic Medicine, Old Road Campus, Roosevelt Drive, Headington, Oxford, OX3 7BN Are you a Postdoctoral Research Scientist with experience in iPS cell biology and transcriptomics? The Hallegger Group at the Oxford-GSK Institute for Molecular & Computational Medicine (IMCM) addresses the question of what transcriptomic changes are linked to the earliest stages in neurodegeneration. We have a new opportunity for a highly motivated Postdoctoral Research Scientist to join the team, to undertake multidisciplinary approaches to discover and validate transcriptomic changes associated with changes in the condensation behaviour of TDP-43 an RNA-binding protein central to Motor Neuron Disease (MND) and ALS (Amyotrophic lateral sclerosis). Recent work from Dr. Hallegger’s team has demonstrated, by taking an interdisciplinary approach, how RNA- and condensation-dependent assemblies affect transcriptome-wide RNA networks. This work in the increasingly important field of membrane-less organelles/condensates describes how the TDP-43 condensation properties specify its RNA binding and regulatory repertoire. As the Postdoctoral Research Scientist, your responsibilities will include the culture/characterisation of iPSC-derived neuronal models, generating novel cell lines with mutations in RNA binding proteins relevant to MND using CRISPR-Cas9 genome editing, and undertaking cellular and biochemical assays using advanced techniques in cell and molecular biology, proteomics and cell imaging. You will utilise bulk, long-read and iCLIP RNA-sequencing approaches to look at gene expression and regulation changes to identify proteins/pathways linked to the condensation behaviour of RNA binding proteins. It is essential that you hold a PhD/DPhil (or close to completion) in Neuroscience, Biology, Molecular Biology, or related area, and you will have experience in human induced pluripotent stem cell-derived neuronal models. You will have experience in cell culture, molecular and cell biology, protein biochemistry and setting up cellular assays, and demonstrable experience in microscopy. Experience in the field of neurodegeneration, particularly in ALS-FTLD/MND/Frontotemporal Dementia is highly desirable for this role. Interviews will be held in the week commencing 6 January 2025.